The publication aims to compare the risk of cardiovascular events between SGLT2 and DPP-4 inhibitors among people with type 2 diabetes.
Citation
Filion K B, Lix L M, Yu O H, Dell’Aniello S, Douros A, Shah B R et al. Sodium-glucose cotransporter 2 inhibitors and risk of major adverse cardiovascular events: multi-database retrospective cohort study BMJ 2020; 370 :m3342 doi:10.1136/bmj.m3342